ES2140652T3 - Uso de n-alquil-derivados de 1,5-didesoxi-1,5-imino-d-glucitol para el tratamiento de infecciones por el virus de la hepatitis b. - Google Patents

Uso de n-alquil-derivados de 1,5-didesoxi-1,5-imino-d-glucitol para el tratamiento de infecciones por el virus de la hepatitis b.

Info

Publication number
ES2140652T3
ES2140652T3 ES95905416T ES95905416T ES2140652T3 ES 2140652 T3 ES2140652 T3 ES 2140652T3 ES 95905416 T ES95905416 T ES 95905416T ES 95905416 T ES95905416 T ES 95905416T ES 2140652 T3 ES2140652 T3 ES 2140652T3
Authority
ES
Spain
Prior art keywords
glucitol
hepatitis
treatment
alkyl
virus infections
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES95905416T
Other languages
English (en)
Inventor
Timothy M Block
Baruch S Blumberg
Raymond A Dwek
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GD Searle LLC
Monsanto Co
Original Assignee
GD Searle LLC
Monsanto Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by GD Searle LLC, Monsanto Co filed Critical GD Searle LLC
Application granted granted Critical
Publication of ES2140652T3 publication Critical patent/ES2140652T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

SE PRESENTA UN METODO PARA EL TRATAMIENTO DE LAS INFECCIONES POR EL VIRUS DE LA HEPATITIS B (HBV) QUE COMPRENDE LA ADMINISTRACION AL ANFITRION INFECTADO DE UN DERIVADO DE N-ALQUILO DE 1,5-DIDEOXI-1,5-AMINO-D-GLUCITOL EN EL CUAL EL GRUPO DE ALQUILO CONTIENE ENTRE 3 Y 6 ATOMOS DE CARBONO.
ES95905416T 1994-01-13 1994-12-23 Uso de n-alquil-derivados de 1,5-didesoxi-1,5-imino-d-glucitol para el tratamiento de infecciones por el virus de la hepatitis b. Expired - Lifetime ES2140652T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US18151994A 1994-01-13 1994-01-13

Publications (1)

Publication Number Publication Date
ES2140652T3 true ES2140652T3 (es) 2000-03-01

Family

ID=22664619

Family Applications (1)

Application Number Title Priority Date Filing Date
ES95905416T Expired - Lifetime ES2140652T3 (es) 1994-01-13 1994-12-23 Uso de n-alquil-derivados de 1,5-didesoxi-1,5-imino-d-glucitol para el tratamiento de infecciones por el virus de la hepatitis b.

Country Status (14)

Country Link
US (1) US6037351A (es)
EP (1) EP0739205B1 (es)
JP (1) JP3628021B2 (es)
KR (1) KR100348657B1 (es)
CN (1) CN1074921C (es)
AT (1) ATE186836T1 (es)
AU (1) AU1403795A (es)
CA (1) CA2181033C (es)
DE (1) DE69421828T2 (es)
DK (1) DK0739205T3 (es)
ES (1) ES2140652T3 (es)
GR (1) GR3032527T3 (es)
PT (1) PT739205E (es)
WO (1) WO1995019172A1 (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030100532A1 (en) * 1997-02-14 2003-05-29 Gary S. Jacob Use of n-substituted-1,5-dideoxy-1,5-imino-d-glucitol compounds in combination therapy for treating hepatitis virus infections
PT1030839E (pt) 1997-11-10 2004-05-31 Searle & Co Utilizacao de iminoacucares para tratar a resistencia a multifarmacos
US6689759B1 (en) 1998-02-12 2004-02-10 G. D. Searle & Co. Methods of Treating hepatitis virus infections with N-substituted-1,5-dideoxy-1,5-imino-d-glucitol compounds in combination therapy
DE69932154T2 (de) * 1998-02-12 2007-05-31 G.D. Searle Llc, Chicago Verwendung von n-substituirten-1,5-dideoxy-1,5-imino-d-glucitolen zur behandlung von hepatitis infektionen
EP1714676A3 (en) * 1998-02-12 2006-11-15 G.D. Searle LLC. Use of N-substituted-1,5-dideoxy-1,5-imino-D-glucitol compounds for treating hepatitis virus infections
US6274597B1 (en) 1998-06-01 2001-08-14 Mount Sinai School Of Medicine Of New York University Method of enhancing lysosomal α-Galactosidase A
EP1658846B1 (en) * 1999-02-12 2008-07-30 United Therapeutics Corporation N-(8,8,8-trifluorooctyl)-1,5-dideoxy-1,5-imino-D-glucitol for treating hepatitis virus infections
ATE402701T1 (de) * 1999-02-12 2008-08-15 United Therapeutics Corp N-(8,8,8-trifluorooctyl)-1,5-dideoxy-1,5-imino- - glucitol zur behandlung von hepatitis-virus- infektionen
JP2003505501A (ja) 1999-02-12 2003-02-12 ジー・ディー・サール・アンド・カンパニー 肝炎ウィルス感染の処置のためのグルカミン化合物
ES2302697T3 (es) 1999-08-10 2008-08-01 The Chancellor, Masters And Scholars Of The University Of Oxford Compuestos n-alquilicos de cadena larga y derivados oxa de los mismos y uso como composiciones antivirales.
JP2003522791A (ja) * 2000-02-14 2003-07-29 ファルマシア コーポレイション 肝炎ウイルス感染症治療用ｎ‐置換‐１，５‐ジデオキシ‐１，５‐イミノ‐ｄ‐グルシトール化合物の使用
US20060052414A1 (en) * 2004-08-13 2006-03-09 Migenix, Inc. Compositions and methods for treating or preventing Hepadnaviridae infection
CN104876855A (zh) 2006-05-24 2015-09-02 联合治疗公司 脱氧吉瑞霉素和d-阿拉伯胶素醇类似物及使用方法
KR20090057035A (ko) * 2006-08-21 2009-06-03 유나이티드 세러퓨틱스 코오포레이션 바이러스 감염의 치료를 위한 병용 요법
US8097728B2 (en) 2007-04-30 2012-01-17 Philadelphia Health & Education Corporation Iminosugar compounds with antiflavirus activity
JP2013233113A (ja) * 2012-05-09 2013-11-21 Osaka Univ 物理的負荷への耐性が向上した細胞の製造方法
RU2743694C1 (ru) * 2019-12-04 2021-02-24 Общество с ограниченной ответственностью "29 февраля" Миглустат N-бутил-1,5-дидезокси-1,5-имино-D-глюцит

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1555654A (en) * 1977-06-25 1979-11-14 Exxon Research Engineering Co Agricultural burner apparatus
US4849430A (en) * 1988-03-09 1989-07-18 Monsanto Company Method of inhibiting virus
US4957926A (en) * 1988-12-22 1990-09-18 Monsanto Company Method of treating herpesviruses
US5030638A (en) * 1990-02-26 1991-07-09 G. D. Searle & Co. Method of antiviral enhancement

Also Published As

Publication number Publication date
CN1074921C (zh) 2001-11-21
PT739205E (pt) 2000-04-28
AU1403795A (en) 1995-08-01
DK0739205T3 (da) 2000-05-01
KR100348657B1 (ko) 2003-08-02
WO1995019172A1 (en) 1995-07-20
ATE186836T1 (de) 1999-12-15
EP0739205B1 (en) 1999-11-24
JP3628021B2 (ja) 2005-03-09
JPH09508111A (ja) 1997-08-19
GR3032527T3 (en) 2000-05-31
US6037351A (en) 2000-03-14
EP0739205A1 (en) 1996-10-30
CN1149253A (zh) 1997-05-07
DE69421828T2 (de) 2000-04-20
CA2181033A1 (en) 1995-07-20
CA2181033C (en) 2007-09-04
DE69421828D1 (de) 1999-12-30

Similar Documents

Publication Publication Date Title
ES2140652T3 (es) Uso de n-alquil-derivados de 1,5-didesoxi-1,5-imino-d-glucitol para el tratamiento de infecciones por el virus de la hepatitis b.
PY0111577A (es) Métodos y composiciones para el tratamiento del virus de la hepatitis c
MXPA02012443A (es) Profarmaco en 3'' de 2'-desoxi-beta-l-nucleosidos.
DE69735634D1 (de) Substituierte cyclopentanderivate die als neuramidase-inhibitoren nuetzlich sind
MD1507G2 (ro) Inhibitori, compoziţie farmaceutică pe baza lor şi procedeu de inhibare a HIV proteazei
DE60105424D1 (de) Methoden zur behandlung von delta hepatitis virus infektionen mit beta-l-2' deoxy-nucleosiden
DE69534264D1 (de) Facettenreiches verfahren zur unterdrückung der vermehrung latenter viren in menschen und tieren
ES2098029T3 (es) Vacunas de hepatitis que contienen monofosforil lipido a 3-o-desacilado.
MD1838F2 (en) 5,6-dichlorbenzimidazole derivatives, process for obtaining thereof, pharmaceutical composition and method of treatment or prevention of herpetic viral infections
EP1852121A3 (en) Lipid analogs for treating viral infections
BR9907882A (pt) Uso de compostos de 1,5-didesóxi-1,5-imino-d-glucitol n-substituìdos para o tratamento de infecções de vìrus de hepatite
ES2108969T3 (es) Utilizacion de analogos de didesoxinucleosidos en el tratamiento de infecciones virales.
ES2123048T3 (es) Analogos de nucleosidos antiviricos.
DK0391644T3 (da) Arylsubstituerede rhodaninderivater
ATE339211T1 (de) L-fmau zur behandlung von hepatitis-delta-virus- infizierung
NL300188I1 (nl) Acellulair vaccin.
ES2062165T3 (es) Derivado de piperidina, metodo para su preparacion, y una composicion farmaceutica que comprende el mismo.
ATE220332T1 (de) Behandlung von hepatitis b mit thymosin alpha 1 und lamivudin
DE69019404D1 (de) Derivate von Penciclovir zur Behandlung von Hepatitis-B-Infektionen.
ES2014042A6 (es) Un procedimiento para la preparacion de una composicion de 1-(2'-desoxi -2' fluor -b- d- arabinofuranosil) -5-etiluracilo.
CO5090912A1 (es) COMBINACION NOVEDOSA DE VACUNAS COMPRENDIENDO UN POLISACARI- DO Vi Salmonella typhi PURIFICADA Y POR LO MENOS OTRO ANTIGE NO Y METODOS PARA HACER LAS VACUNAS
GT199000061A (es) Derivados amino acidos
RS20120367A3 (en) METHODS AND MIXTURES FOR TREATMENT OF VIRAL HEPATITIS C
MXPA94003453A (es) Metodo y composicion para el tratamiento de pacientes con hepatitis b que tienen descompensacion hepatica.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 739205

Country of ref document: ES